Clinical trial
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent…
NCT00050440 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00050440 |
|---|---|
| Title | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma |
| Official title | A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | PharmaMar Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms |
| Intervention type | Drug |
| Interventions | Trabectedin, Dexamethasone |
| Enrollment | 50 |
| Start date | Jul 1, 2002 |
| Completion | Jul 1, 2004 |
| First posted | Dec 10, 2002 |
| Last update posted | Jan 8, 2013 |
| Countries | Canada, Netherlands, Russia, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: